$THC

HCA Healthcare (HCA) reported Q2 revenue of $20.23B, up 8.7% YoY, exceeding estimates by 2.4%. Tenet Healthcare (THC) saw revenue of $5.63B, up 6.8%, beating estimates by 3.9%. Universal Health Services (UHS) reported $4.64B, up 8.3%, exceeding estimates by 1.1%. Acadia Healthcare (ACHC) reported $865.8M, flat YoY, topping estimates by 2%. HCA and Tenet stocks rose 24.5% and 34.3% post-earnings, respectively, while Acadia fell 5%.

Guggenheim reaffirmed a Buy rating for Tenet Healthcare with a $307 price target, suggesting 11.6% upside from the Oct 15 close. The firm expects 2026 revenue of $22.22B and 8.1% EBITDA growth, citing operational strength and cost efficiency. Tenet's cash position supports acquisitions and share buybacks, potentially boosting stock performance.

Argus raised its target price for Tenet Healthcare (THC) to $294.00. The company operates 47 hospitals and over 500 outpatient facilities in the US, mainly in the South. This update may impact investor sentiment and trading activity for THC.

Cantor Fitzgerald reaffirmed its Overweight rating on Tenet Healthcare (NYSE:THC) with a $270 price target, citing stable labor conditions and strong financial performance. The stock has gained 36% in six months and trades at a P/E ratio of 10.16. Other analysts have also raised price targets, while BMO Capital initiated coverage with a Market Perform rating. A director's share sale was recently disclosed.

The FTC sent letters to 24 major healthcare companies, including HCA Healthcare, Tenet Healthcare, Community Health Systems, and Universal Health Services, warning them to provide accurate and timely pricing information to patients. The FTC emphasized that deceptive pricing practices are prohibited, and companies must comply with transparency regulations.

Tenet Healthcare (THC) issued $2b in 6.250% senior notes due 2034 to refinance existing debt. Its share price has risen 25.4% in 90 days and 29.7% year-to-date. The company's fair value is estimated at $260, slightly above its current price of $258.62. Management's cost-reduction efforts have lowered contract labor and certain analytics costs, but further margin expansion may be limited.

Cantor Fitzgerald maintained an Overweight rating on Tenet Healthcare (THC) with a $270 price target, citing strong 2027 visibility and attractive valuation. Analysts highlight inpatient volume outlooks and quantified headwinds. Recent upgrades from Raymond James, UBS, and Guggenheim contrast with BMO's Market Perform rating. Director Richard Mark sold 10,000 shares at $263.42 each.

Argus lowered its target price for Tenet Healthcare (THC) to $283.00. The company operates 47 hospitals and over 500 outpatient facilities in the US, mainly in the South. This update may impact investor expectations for THC's stock performance.

Tenet Healthcare (THC) reported a 27.1% year-over-year increase in operating cash flow to $2.2B in H1 2026, raising its adjusted free cash flow guidance to $1.825B-$2.055B. The company spent $1.4B on share buybacks and increased its repurchase authorization by $2B. THC is balancing buybacks with growth investments, expecting $700M-$800M in capital spending. Peers UHS and HCA also reported significant buybacks and capital investments.

Tenet Healthcare (THC) is focusing on its ambulatory business for growth, with BMO Capital Markets noting favorable long-term trends and margins. USPI, Tenet’s ambulatory platform, reported 9.3% revenue growth in Q2. BMO initiated coverage with a Market Perform rating and $265 price target. Hedge funds increased stakes, while short interest declined. Risks include reimbursement changes and competition.